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Abstract: The biology of cancer is critically reviewed and evidence adduced that its development can be
modelled as a somatic cellular Darwinian evolutionary process. The evidence for involvement of genomic instability
(GI) is also reviewed. A variety of quasi-mechanistic models of carcinogenesis are reviewed, all based on this
somatic Darwinian evolutionary hypothesis; in particular, the multi-stage model of Armitage and Doll (Br. J. Cancer
1954:8;1-12), the two-mutation model of Moolgavkar, Venzon, and Knudson (MVK) (Math. Biosci. 1979:47;55-77), the
generalized MVK model of Little (Biometrics 1995:51;1278-1291) and various generalizations of these incorporating
effects of GI (Little and Wright Math. Biosci. 2003:183;111-134; Little et al. J. Theoret. Biol. 2008:254;229-238).
Reviewers: This article was reviewed by RA Gatenby and M Kimmel.
Synopsis
The biology of cancer is reviewed and evidence adduced
that it can be modelled as a somatic cellular Darwinian
evolutionary process; evidence for involvement of geno-
mic instability is also reviewed.
Introduction
In this review article we shall critically review evidence
on initiation and progression of cancer. In particular we
shall attempt to justify why cancer can be treated as a
somatic cellular Darwinian evolutionary process. A vari-
ety of quasi-mechanistic models of carcinogenesis will
be reviewed, all based on this somatic Darwinian evolu-
tionary hypothesis; in particular, the multi-stage model
of Armitage and Doll [1], the two-mutation model of
Moolgavkar, Venzon, and Knudson (MVK) [2,3], a mul-
tistage generalization of the MVK model of Little [4]
and various generalizations of these incorporating effects
of transmissible genomic instability (GI) [5,6]. In the
“Biological background” section we shall review the
basic biological data, and in the section “Genomic
instability and somatic cellular Darwinian evolution in
cancer” we shall examine the evidence for GI as an initi-
ating event in cancer. In the section “Is somatic cellular
Darwinian evolution in cancer plausible?” we shall con-
sider the evidence for regarding development of cancer
as a somatic Darwinian evolutionary process. Finally in
the section “Carcinogenesis models and somatic cellular
Darwinian evolution” we shall consider in turn various
stochastic cancer models developed and widely
employed in the last 50 years, all based on this
hypothesis.
Biological background
The biology of cancer is a vast subject and inevitably in
a review of this nature one can only touch on what
might be regarded as the more important and relevant
themes - those needing more background biology are
advised to consult one of number of basic texts, for
example, the recent book by Weinberg [7].
Cancer is a group of diseases characterized by autono-
mous, uncontrolled cell proliferation, evasion of cell death,
self-construction of oxygen and nutrient supply and
spreading of cancerous cells through metastasis [7,8]. An
early hypothesis postulated that the onset of cancers was a
consequence of virus infections (see, for example, Stanley
[9] for a review). Although many retroviruses and DNA
viruses were identified in animal leukaemias and occasion-
ally in human leukaemias [10-12], the vast majority of
these ‘cancer-related’ viruses were not aetiologically
involved in human cancers [10,12][7] (chapter 3) and only
a few were direct carcinogens [13,14][7] (chapter 3). How-
ever, investigation of such viruses led to the discovery of
the first human oncogene, v-src, whose nucleic acid
sequences are similar to those of its viral homologue [15].
Together with the subsequent identification of tumour
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any medium, provided the original work is properly cited.suppressor genes (TSG), the understanding of cancer ori-
gin has since been extended from external carcinogenic
agents (i.e., retroviruses andc h e m i c a lc a r c i n o g e n s )t o
alterations in the host genome [16,17][7] (chapter 11). The
key tenet of the latter understanding is that cancer results
from accumulation of changes to the DNA in somatic
cells [18,18-20][7] (chapter 11). These data and others
consistently identify modifications to key components in
the somatic cell genome as responsible for initiating and
sustaining the cancer process. We review this literature in
the section “Genomic instability and somatic cellular Dar-
winian evolution in cancer” below.
Cells divide by duplicating their genetic material, a
process termed the cell cycle. This consists of five
distinct phases, G0 (quiescent), G1, S (synthesis), G2
(G1+S+G2 are collectively known as interphase) and M
phase (mitosis). M phase is itself composed of two
tightly coupled processes: mitosis, in which the cell’s
chromosomes are divided between the two daughter
cells, and cytokinesis, in which the cell’sc y t o p l a s m
divides forming distinct cells. Since integrity of the gen-
ome, and in particular chromosomes, is crucial in main-
taining normal cell function, the cell cycle is closely
monitored at various checkpoints [7] (chapter 8). In par-
ticular, the APC [21], p53 and RB1 [22,23] genes have
been implicated in G1/S checkpoint control. Detection
of DNA damage in cells may result in cell cycle arrest
so that damage can in some cases be repaired [24,25][7]
(chapter 8) or the damaged cells may undergo apoptosis
[26,7] (chapter 8). In addition, during DNA segregation,
the spindle assembly checkpoint ensures that all chro-
mosomes are properly connected by the mitotic spindle
[27,28].
DNA mutations occur randomly or as a result of exo-
genous mutagenic exposures. The majority of these
mutations have little or no effect (e.g., silent mutations).
Furthermore, depending on the nature of the damage,
some can be repaired by specific DNA repair mechan-
isms. Base excision repair deals efficiently and accurately
with single base damage, utilizing the intact comple-
mentary DNA strand as the template for repair [29][7]
(chapter 12). On the other hand, double strand breaks
(DSBs), resulting from cuts in both DNA strands, are
more complex and potentially more detrimental. There
are two major DSB repair mechanisms, namely non-
homologous end joining (NHEJ) and homologous
recombination (HR) [7] (chapter 12). NHEJ repairs the
damage by simply merging the two ends of the break
through DNA ligation. HR repairs the breaks either by
using sequences in a homologous chromosome or a sis-
ter chromatid as the repair template or through single
strand annealing (SSA) [7] (chapter 12). In the latter
case the intervening region between two identical
repeated sequences residing on either side of the DSB is
removed and the two repeated sequences are merged. In
each case, HR requires the presence of homologous
DNA sequences, which reduces the potential errors in
repair. In contrast, because of the lack of a complemen-
tary repairing template, NHEJ is particularly error-prone
[29][7] (chapter 12). Mis-ligation of the two ends
resulted from NHEJ, for example, is implicated in chro-
mosome translocations in acute lymphoid leukaemia
[30].
Whether induced by exogenous or endogenous muta-
gens or introduced during reconstruction of the
damaged DNA, either a single base pair can be modified
or there can be a larger-scale event such as gain or loss
of a chromosome segment. A mis-sense mutation
replaces the original amino acid with a different one
while a nonsense mutation shortens the affected protein
sequence and ultimately leads to protein degradation.
Due to the absence of a particular protein or a group of
proteins, mis-sense and nonsense mutations are often
lethal to the affected cell. In addition, insertion or dele-
tion of base pairs can lead to frameshift mutations,
which may completely change the protein sequence.
Chromosomal abnormalities, that is to say large scale
alterations to the DNA, be they deletions, duplications
or translocations, can have more severe effects. Chromo-
some translocations occur when a stretch of DNA is
moved from its original chromosomal position to
another position and may result from mis-repair of
DSBs and mutations in DNA-repair pathways [31]. Spe-
cific chromosome translocations are observed in both
acute myeloid leukaemia, in which positions q22 on
both chromosomes 8 and 21 are frequently exchanged
[32], and chronic myeloid leukaemia, characterized by
the presence of the BCR-ABL hybrid gene that increases
the rate of division and evades apoptosis [33]. Such
abnormalities can result in amplification of a chromo-
some region and consequent over-production of relevant
protein; deletion and loss of heterozygosity (LOH) will
lead to loss of one or both copies of certain genes and
their products. Deletion of the chromosome regions
containing the BRCA1 and BRCA2 genes, for example,
are commonly observed in inherited ovarian cancer and
breast cancer [34,35] and complete inactivation of the
APC gene, a tumour suppressor gene related to a num-
ber of cancers, is caused by LOH in oesophageal and
non-small cell lung cancer [36,37] and other specific
cancer types [7] (chapter 7).
When a mutation changes a gene in the germ line
cells, it may be passed on to offspring, whose compo-
nent cells, as a result, all contain a defective copy of the
gene. For example, compared with children who are
born with a normal, intact RB1 gene, those born with a
germinal mutation in one of the two RB1 alleles have an
enhanced risk of developing retinoblastoma (RB), a
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contrast to the sporadic (homozygous) cases, over 60%
of the inherited RB cases are bilateral, i.e., tumours
appear in both eyes [38]. Although germ-line mutations
are relatively rare, the inherited defects exhibited in all
cells in the body predispose the heterozygous individual
to various genetic disorders, including cancers.
Mutations to somatic cells, like their germinal coun-
terparts, may cause diseases in the host organ. As indi-
cated above, there are two main classes of genes directly
involved in carcinogenesis, oncogenes and TSGs [27][7]
(chapters 4, 7). Activation of an oncogene requires only
a single mutation to one of the two homologous alleles
of a proto-oncogene; the remaining intact allele cannot
compensate for the resulting dominant oncogenic
defect. In contrast, TSGs are recessive, i.e., one wild-
type allele of the gene can maintain normal function.
Complete inactivation of the growth suppression func-
tion from TSGs, as for example in RB, therefore,
requires two mutations.
Immortality is a distinctive characteristic of cancer
cells. It is known that normal somatic cells can only
divide up to a limited number of times (the Hayflick
limit) and once this limit is reached, they enter replica-
tive senescence and lose the ability to divide further
[40,41][7] (chapter 10). Telomere shortening is a possi-
ble mechanism implicated in limiting a cell’s division
potential [41]. In humans, the telomere is a sequence of
several thousand repeats (TTAGGG) residing at the end
of every chromosome. Its existence prevents the loss of
vital genetic information at each end of the chromo-
somes and protects genomic integrity by inhibiting
chromosomal fusions (joining of two chromosomes)
[42][7] (chapter 10). The loss of a certain length of the
telomere after each cell division gradually diminishes
the cell’s division potential and ultimately leads to cell
senescence or death [43][7] (chapter 10). By contrast,
telomeres in most cancer cells remain above the critical
length so that the restriction on division number
imposed by telomere shortening is lifted and hence can-
cer cells can multiply without limit [44][7] (chapter 10).
One mechanism in cancer cells to counteract telomeric
shortening is activation of telomerase, an enzyme that
maintains the length by adding the hexanucleotide onto
the end of the telomere [45,46][7] (chapter 10).
Although 85-90% of tumour cells express telomerase, a
certain proportion of such cells do not [47][7] (chapter
10); the precise mechanisms by which these cells main-
tain telomere length are unclear, although an interchro-
mosomal copying mechanism is implicated [48][7]
(chapter 10).
When a cell has acquired the malignant phenotype,
classically it is assumed to multiply quickly to a clini-
cally overt tumour. However, like normal tissues,
tumours require an adequate supply of oxygen, metabo-
lites and an effective way to remove waste products
[49,7] (chapter 13). However, these requirements vary
among tumour types, and change over the course of
tumour progression [50]. Gaining access to the host vas-
cular system and the generation of a tumour blood sup-
ply are rate-limiting steps in tumour progression, and
require what has been termed an “angiogenic switch”
[51][7] (chapter 13). The interaction of the tumour with
the microvasculature is discussed in a bit more detail
below.
Genomic instability and somatic cellular
Darwinian evolution in cancer
As cells acquire subsequent mutations, they acquire
selective advantage over cells not having these muta-
tions, manifest in a loss of cell cycle control, lack of
response to external signals and ultimately higher rates
of cell turnover. As such this corresponds to a process
that might be termed “somatic Darwinian evolution”
[52,53]. Vineis and Berwick [54] present a variety of evi-
dence that suggests that the somatic development of
cancers in populations arise as a result of selective pres-
sures induced by a variety of environmental stimuli.
Gatenby et al. [55] and Smallbone et al. [56] have con-
structed cancer models allowing for precisely this fea-
ture, as we discuss in the sub-section “Malignant cell
growth and clonal extinction”. We discuss this critical
assumption in more detail in the section “Is somatic cel-
lular Darwinian evolution in cancer plausible?” below.
The classical view is that the cellular “mutations” are
g e n e t i co rp o s s i b l ye p i g e n e t i ce v e n t st h a ta r ec l o n a l l y
expressed in all cells and their descendents. Consistent
with this, and as outlined by Harris [57] (but see also
UNSCEAR [58]), there is compelling biological data to
suggest that cancer arises from a failure of cell differen-
tiation, and that it is largely unicellular in origin. There
is also a large body of data, which does not necessarily
contradict this hypothesis, showing the importance of
the micro-environment in initiating and modifying
tumour growth, indeed in tumour reversion, at least for
certain tumour types (e.g., breast cancer) [59-66]. This
has been termed the “field” theory. As discussed above,
tumour growth requires additional vascular growth, the
so-called “angiogenic switch” [51] [7] (chapter 13), with-
out which it will not grow or metastasize. However, the
importance of the micro-environment for the induction
(rather than progression) of a large number of types of
cancer has been disputed, since for many tumours there
is clear evidence of clonality [57,58,63,67]. There is bio-
logical data suggesting that the initiating lesion in the
multistage process leading to cancer might be one invol-
ving a destabilization of the genome resulting in eleva-
tion of mutation rates, reviewed by Morgan [68,69].
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“caretaker” genes, responsible for maintaining genomic
integrity [70], as opposed to the “gatekeeper” TSGs and
proto-oncogenes discussed above. This destabilization
would be expected to result in non-clonal expression of
various mutations. Loeb [71,72] has presented evidence
that an early step in carcinogenesis is mutation in a
gene controlling genome stability. Stoler et al.[ 7 3 ]
showed that there are 11,000 mutations per carcinoma
cell for a number of different cancer types, again imply-
ing that genomic destabilization is an early event in car-
cinogenesis. In particular,t h e r ei sd a t at os u g g e s t
existence of such an early genomic destabilization event
for colon cancer [71-73].
There is known to be heterogeneity in the types of GI
that occur, particularly for colon cancer. The majority of
human cancers exhibit chromosomal instability (CIN),
characterized by cells having a large number of acquired
abnormalities at the chromosomal level, expressed as
gain or loss of large chromosome fragments, changes in
chromosome number [74,75] and LOH [27]. A large
proportion of colon cancers express loss of chromosome
arms, often containing specific tumour suppressor genes
such as p53 (17p), SMAD4 and APC (5q) [18]. However,
about 17% of colon cancers [76], as well as a generally
smaller portion of other solid cancers [77], exhibit
microsatellite instability (MIN), a less prevalent form of
GI. MIN is caused by defects in the mismatch repair
(MMR) mechanism, which contributes to replication
fidelity by correcting incorrectly inserted DNA bases
[27][7] (chapter 12). Defects in the MMR pathway lead
to frequent insertions and deletions of repetitive short
sequences, so-called microsatellites, across the genome.
Several genes involved in MMR have been discovered in
humans, for example, the hMSH2 gene on chromosome
2p16 [78,79] and the hMLH1 gene on chromosome
3p21-23 [80,81]. MIN is predominantly associated with
hereditary non-polyposis colorectal cancer (HNPCC),
but is not often seen in sporadic cases. In most HNPCC
cases, patients exhibit cells that contain one mutant
allele of the hMSH2 gene, inherited from either the
paternal or maternal carrier, and one normal allele
[78,79]. The existence of the wild-type allele acts domi-
nantly, maintaining the mismatch repair function. If a
sporadic mutation inactivates the remaining normal
allele, the cell expresses the MIN phenotype, which
results in an enhanced microsatellite and point mutation
rate [27]. However, cancers from HNPCC patients are
generally chromosomally normal, while MMR proficient
tumours are generally aneuploid and highly chromoso-
mally unstable [27]. Breivik [82,83] presents evidence
that GI arises as a result of selection of cells in relation
to specific mutagens in the environment; in particular
he argues that the tissue specificity of CIN and MIN
within the colon may result from adaptive selection
associated with exposure to different agents, for which
there is experimental support [84]. Chow and Rubin
[85] demonstrate that cell selection is sufficient to
explain the apparently increased mutation rates
observed in cloned cell sub-populations in vitro -t h e
assumption of GI is not required.
However, the question of whether chromosomal
instability is the initiating event in carcinogenesis, even
in relation to colon cancer (where the evidence is stron-
gest), is controversial. Tomlinson et al. [86] point out
that conventional mutation rates are entirely adequate
to account for the observed incidence of colon cancer.
Tomlinson and Bodmer [87] argue that cancer is an
evolutionary process, and that the observed accumula-
tion of chromosomal and other damage in colon cancers
may simply be the result of selection for cells with
growth advantage, with mutations “piggy-backing” on
this process of selection. As above, Chow and Rubin
[85] present experimental in vitro evidence that also
s u g g e s t st h a tG Ii sn o tn e c e s s a r yt oi n d u c en e o p l a s t i c
transformation - selection is sufficient. Much other evi-
dence on the importance of cell selection for carcino-
g e n e s i si sr e v i e w e db yR u b i n[ 8 8 ] .A ss h o w nb yL i t t l e
and Li [89] and Little et al. [6] (and as we discuss in the
sub-section “Multiple pathway models incorporating
genomic instability” below), the fact that the two cancer
stage GI model developed by Little and Wright [5] and
similar models allowing for multiple types of GI [6], as
well as the GI model of Nowak et al. [90] fit US Surveil-
lance, Epidemiology and End Results (SEER) colon can-
cer data as well as, but no better than, the non-GI
model of Luebeck and Moolgavkar [91] suggests that,
b a s e do nt h ef i to ft h e s em o dels to this population-
based data, there is little evidence for or against the
involvement of GI in colon cancer.
Is somatic cellular Darwinian evolution in cancer
plausible?
A common assumption of most carcinogenesis models,
in particular all those discussed in the section “Carcino-
genesis models and somatic cellular Darwinian evolu-
tion” below, is that all cell populations are independent,
corresponding to the assumed somatic cellular Darwi-
nian evolution. More rigorously, in mathematical terms
we assume that cells with variable numbers of acquired
mutations are statistically conditionally independent
(conditional on the parental lineage and exogenous
exposures), so that the cell populations may be
described by a branching process. This is assumed for
analytic tractability, but it is difficult to test.
To the extent that it is known that normal cells com-
municate with each other via cell surface markers and
otherwise, this appears unlikely to be precisely true. One
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assumption may appear to break down is the colon. The
colon and small intestine are structured into crypts,
each crypt containing some thousands of cells, and
organized so that the stem cells are at the bottom of the
crypt [92,93]. There is evidence that there may be more
than one stem cell at the bottom of each crypt [94]. The
progeny of stem cells migrate up the crypt and continue
to divide, becoming progressively more differentiated.
The differentiated cells eventually reach the top of the
crypt where they are shed into the intestinal lumen. Pot-
ten and Loeffler [92] and Nowak and colleagues [93,95]
have postulated similar models for cancers of the small
intestine and colon taking account of the linear struc-
ture of the crypts, and in which necessarily the assump-
tion of conditional independence breaks down.
However, if mutation is regarded at the level of the
crypt, then conditional independence of cell lineages is
still likely to be true. Moreover, there is abundant evi-
dence that, in contrast to normal cells, which rely on
mitogenic stimuli, e.g., via TGFb, for proliferation, can-
cer cells do not depend on such external signals, in par-
ticular TGFb, for sustained growth, and are self-
sufficient in this respect [96,97][7] (chapter 5). There is
also data to suggest that inactivation of TGFb signalling
is an early event in pancreatic cancer [98]. To this
extent, tumour and pre-malignant transformed cells are
likely to operate independently of cells in the vicinity, so
that for these cells (the ones of critical importance in
the models discussed above) the hypothesis of condi-
tional statistical independence is not implausible.
However, statistical independence is unlikely to apply
in late-stage processes, for example in the growth of the
malignant cell clone, where there is very likely to be
modulation of cell turnover and necrosis as the tumour
size increases, especially if the angiogenic switch is not
activated.
Carcinogenesis models and somatic cellular
Darwinian evolution
In this section we shall treat the major carcinogenesis
models developed and used over the last 50 years. These
and other models are discussed at greater length by
Little [99].
Armitage-Doll multistage model
One of the more commonly observed patterns in the
age-incidence curves for epithelial cancers is that the
cancer incidence rate varies approximately as C·[age]
b
for some constants C and b [100,101]. The so-called
multi-stage model of carcinogenesis of Armitage and
Doll [1] was developed in part as a way of accounting
for this approximately log-log variation of cancer inci-
dence with age. The model supposes that at age t an
individual has a population of X(t) completely normal
(stem) cells and that these cells acquire one mutation at
ar a t eM(0)(t). The cells with one mutation acquire a
second mutation at a rate M(1)(t), and so on until at the
(k-1) th stage the cells with (k-1) mutations proceed at a
rate M(k-1)(t) to become fully malignant. The model is
illustrated schematically in Figure 1. It can be shown
that when X(t)a n dt h eM(i)(t)a r ec o n s t a n t ,am o d e l
with k stages predicts a cancer incidence rate that is
approximately given by the expression C·[age]
k-1 with
C = X·M(0)·M(1)·...·M(k-1)/(1·2·...·(k-1)) [1,102]. As can be
seen from Figure 2, for colon cancer the age-incidence
relationship is remarkably well described by a power of
age, as predicted by this model.
Departures from this form of relationship are only
apparent at very young ages (< 10 years) (Figure 2). For
many common epithelial cancers in adulthood this func-
tion, C·[age]
k-1, fits the age-incidence and age-mortality
relationships well, with the implied number of rate-lim-
iting stages, k, between 5 and 7 [101]. In the intervening
fifty years, there has accumulated substantial biological
evidence (as reviewed in the sections “Biological back-
ground”, “Genomic instability and somatic cellular Dar-
winian evolution in cancer”, “Is somatic cellular
Darwinian evolution in cancer plausible”)t h a tc a n c e ri s
a multi-step process involving the accumulation of a
number of genetic and epigenetic changes in a clonal
population of cells.
However, there are certain problems with the model
proposed by Armitage and Doll [1] associated with the
fact that, as noted above, to account for the observed
age incidence curve C·[age]
b, between 5 and 7 rate-limit-
ing stages are needed. This large number of stages
implies high mutation rates in order to account for the
observed number of cancers. Moolgavkar and Luebeck
Figure 1 Schematic diagram of the Armitage-Doll [1] multi-stage model.
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datasets describing the incidence of colon cancer in a
general population and in patients with familial adeno-
matous polyposis. Moolgavkar and Luebeck [103] found
that Armitage-Doll models with five or six stages gave
good fits to these datasets, but that both of these models
implied mutation rates that were too high by at least
two orders of magnitude compared with experimentally
derived rates. The discrepancy between the predicted
and experimentally measured mutation rates might be
eliminated, or at least significantly reduced, if account
were to be taken of the fact that the experimental muta-
tion rates are locus-specific. A “mutation” in the sense
in which it is defined in this model might result from
the “failure” of any one of a number of independent
l o c i ,s ot h a tt h e“mutation” rate would be the sum of
the failure rates at each individual locus.
Notwithstanding these problems, much use has been
made of the Armitage-Doll multi-stage model as a fra-
mework for understanding the time course of carcino-
genesis, particularly for the interaction of different
carcinogens [104].
Two-mutation model
In order to reduce the arguably biologically implausibly
large number of stages required by their first model,
Armitage and Doll [105] developed a further model of
carcinogenesis, which postulated a two-stage probabilis-
tic process whereby a cell following an initial transfor-
mation into a pre-neoplastic state (initiation) was
subject to a period of accelerated (exponential) growth.
At some point in this exponential growth a cell from
this expanding population might undergo a second
transformation (promotion) leading quickly and directly
to the development of a neoplasm. Like their previous
model, it satisfactorily explained the incidence of cancer
in adults, but was less successful in describing the pat-
tern of certain childhood cancers.
The two-mutation model developed by Knudson [3] to
explain the incidence of retinoblastoma in children took
account of the process of growth and differentiation in
normal tissues. Subsequently, the stochastic two-muta-
tion model of Moolgavkar and Venzon [2] generalized
Knudson’s model, by taking account of cell mortality at
a l ls t a g e sa sw e l la sa l l o w i n gf o rd i f f e r e n t i a lg r o w t ho f
intermediate cells. The two-stage model developed by
Tucker [106] is very similar to the model of Moolgavkar
and Venzon but does not take account of the differential
growth of intermediate cells. The two-mutation model
of Moolgavkar, Venzon and Knudson (MVK) supposes
that at age t there are X(t) susceptible stem cells, each
subject to mutation to an intermediate type of cell at a
rate M(0)(t). The intermediate cells divide at a rate G(1)
(t); at a rate D(1)(t) they die or differentiate; at a rate M
(1)(t) they are transformed into malignant cells. The
model is illustrated schematically in Figure 3. In contrast
with the case of the (first) Armitage-Doll model, there is
a considerable body of experimental biological data sup-
porting this initiation-promotion type of model (see, e.g.,
[107,108]).
The model has been developed to allow for time-vary-
ing parameters at the first stage of mutation [109]. A
further slight generalization of this model (to account
for time varying parameters at the second stage of
Figure 2 SEER 1973-1999 [164] colon cancer data, and observed data (with 95% confidence intervals (CI), adjusted for overdispersion
[165]), taken from Little [99]. The use of double logarithmic (log-log) axes shows that except for the youngest age group (<10 years) the age-
incidence relationship is well described by C·[age]
k-1.
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who also demonstrated that the excess relative risk pre-
dicted by the model, when the first mutation rate was
subject to instantaneous perturbation, decayed at least
e x p o n e n t i a l l yf o ras u f f i c i e n t l yl o n gt i m ea f t e rt h ep e r -
turbation. The model has been used by Moolgavkar
et al. [111] and Heidenreich et al. [112,113] and many
others to describe the incidence of lung cancer in rats
exposed to radon, and in particular to model the inverse
dose-rate effect that has been observed in this data.
Moolgavkar et al.[ 1 1 4 ] ,L u e b e c ket al. [115], Hazelton
et al. [116], Little et al. [117], Heidenreich et al. [118]
and others have applied the model to describe the inter-
action of radon, smoking and other agents causing lung
cancer in various miner cohorts. The two-mutation
model has also been utilised to describe lung, stomach,
and colon cancer in the Japanese atomic bomb survivor
incidence data [119], and to fit to liver cancer data from
a cohort of Swedish Thorotrast-exposed patients [120].
A curious finding in many analyses of lung cancer in
relation to radon-daughter exposure using the two-
mutation model is that there is significant radon action
on intermediate cell proliferation. This has been
observed in radon-exposed rats [112,113], in the Color-
ado Plateau uranium miners [115,117] and in the Chi-
nese tin miners [116]. This is very much associated with
fits of the two-mutation model, and may reflect the lim-
ited number of parameters that can be modified in this
model. Analyses of rat data using a three-mutation gen-
eralized MVK model (see the sub-section “Generalized
MVK and multistage models” below) did not find any
indications of an effect of radon daughter exposure on
intermediate cell proliferation [113]. Likewise, analysis
of the Colorado Plateau miners using a three-mutation
generalized MVK model (see the sub-section “General-
ized MVK and multistage models” below) did not find
any effect of radon daughter exposure on intermediate
cell proliferation rates [117], and the fit of the three-
mutation model was somewhat better than that of the
two-mutation model (see Figure 4).
Moolgavkar and Luebeck [103] have used models with
two or three mutations to describe the incidence of
colon cancer in a general population and in patients
with familial adenomatous polyposis. They found that
both models gave good fits to both datasets, but that
the model with two mutations implied mutation rates
that were biologically implausibly low, by at least two
orders of magnitude. The three-mutation model, which
predicted mutation rates more in line with biological
data, was therefore somewhat preferable. The problem
of implausibly low mutation rates implied by the two-
mutation model is not specific to the case of colon can-
cer, and is discussed at greater length by Den Otter
et al. [121] and Derkinderen et al. [122], who argue that
for most cancer sites a model with more than two stages
is required. A possible way round the problem of
implausibly low mutation rates, at least for colon cancer,
is suggested by the model of Nowak et al.[ 9 3 ] ,w h o
showed that by “washing out” pre-malignant cells in the
intestinal lumen a relatively high mutation rate at the
cellular level may translate into a much lower apparent
mutation rate at the tissue (intestinal crypt) level.
Another problem with the two-mutation model is that
when any of the model parameters are modified, there
are relatively large fluctuations in the hazard function
for carcinogenesis, which start almost as soon as the
Figure 3 Schematic diagram of the two-mutation (MVK)
model [2].
Figure 4 Observed absolute risk of lung cancer mortality
(+95% CI) and predicted risk associated with the optimal two-
mutation and three-mutation models fitted to the Colorado
Plateau uranium miner data as a function of cumulative radon-
daughter exposure, taken from Little et al. [117]
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tially overcome the problem posed by this instantaneous
rise in the hazard after perturbation of the two-mutation
model parameters in their analysis of the Colorado ura-
nium miners data by assuming a fixed period (3.5 years)
between the appearance of the first malignant cell and
the clinical detection of malignancy. However, the use
of such a fixed latent period only translates a few years
into the future the sudden step-change in the hazard.
To achieve the observed gradual increase in risk shortly
after exposure, a stochastic process must be used to
model the transition from the first malignant cell to
detectable cancer, such as is provided by the final stage
(s) in the three- or four-mutation generalized MVK
models used in the analysis of Little [123] of the Japa-
nese atomic bomb survivor data. In particular, an expo-
nentially growing population of malignant cells could be
modelled by a penultimate stage with G(k-1) > 0 and D
(k-1) = 0, the probability of detection of the clone being
determined by M(k-1). Alternatively, to allow for possible
stochastic extinction of malignant clones (e.g., as a result
of failure of the angiogenic switch) one could have a
birth-death process, allowing both G(k-1) > 0 and D(k-1)
> 0. Tan [124] has constructed an explicit model of such
a process with time-varying G(k-1)(t)a n dD(k-1)(t). In
their analysis of lung, stomach and colon cancer in the
Japanese atomic bomb survivor incidence data Kai et al.
[119] did not assume any such period of latency, perhaps
because of the long period after the bombings (12.4
years) before solid cancer incidence follow-up began in
the Life Span Study (LSS). There are other ways in which
an observed gradual increase in tumour risk after para-
meter perturbation could be achieved, in particular by
assuming a random tumour growth rate, or by using a
quantal response rate, relating probability of tumour
detection to size, as outlined by Bartoszyński et al. [125].
Generalized MVK and multistage models
A number of generalizations of the Armitage-Doll and
two- and three-mutation models have been developed
[4-6,108]. In particular, two closely related models have
been developed, whose properties have been described
in the paper of Little [4]. The models generalize the
two-mutation model of Moolgavkar, Venzon, and Knud-
son, and also the Armitage-Doll model, and will be
termed the generalized MVK model. For the general-
ized MVK model it may be supposed that at age t there
are X(t) susceptible stem cells, each subject to mutation
to a type of cell carrying an irreversible mutation at a
rate of M(0)(t). The cells with one mutation divide at a
rate G(1)(t); at a rate D(1)(t) they die or differentiate.
Each cell with one mutation can also divide into an
equivalent daughter cell and another cell with a second
irreversible mutation at a rate M(1)(t). For the cells with
two mutations there are also assumed to be competing
processes of cell growth, differentiation, and mutation
taking place at rates G(2)(t), D(2)(t), and M(2)(t), respec-
tively, and so on until at the (k-1)th stage the cells
which have accumulated (k-1)mutations proceed at a
rate M(k-1)(t) to acquire another mutation and become
malignant. The model is illustrated schematically in Fig-
ure 5. The two-mutation model of Moolgavkar, Venzon,
and Knudson corresponds to the case k = 2. The classi-
cal Armitage-Doll multi-stage model corresponds to the
case in which the intermediate cell proliferation rates G
(i)(t) and the cell differentiation rates D(i)(t) are all zero.
It can be shown [4] that the excess risk for either
model following a perturbation of the parameters will
tend to zero as the attained age tends to infinity. One
can also demonstrate that perturbation of the para-
meters M(k-2), M(k-1), G(k-1), and D(k-1) will result in
an almost instantaneous change in the cancer rate [4].
In particular, this demonstrates that only models with
Figure 5 Schematic diagram of the generalized MVK model [4].
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without instantaneous modification of the cancer
hazard.
Generalized MVK models have been fitted to a num-
ber of datasets, in particular the Japanese atomic bomb
survivor LSS Report 11 mortality data [123,126] and the
Colorado Plateau uranium miners [117], as well as a
group of radon-exposed rats [113], and give good fit,
with in all cases the three-mutation model fitting at
least as well as, and in some cases better than [117] (see
also Figure 4), a model with two mutations. Little et al.
[127] also showed that the age-incidence relationship for
lymphocytic leukaemia incidence in the UK population
could be adequately described by models with either
two or three stages.
Multiple pathway models
Little et al. [128] fitted a generalization of the Armitage-
Doll model to the Japanese atomic bomb survivor and
IRSCC leukaemia data which allowed for two cell popu-
lations at birth, one consisting of normal stem cells car-
rying no mutations, the second a population of cells
each of which has been subject to a single mutation.
The leukaemia risk predicted by such a model is equiva-
lent to that resulting from a model with two pathways
between the normal stem cell compartment and the
final compartment of malignant cells, the second path-
way having one fewer stage than the first. This model
fitted the Japanese and International Radiation Study of
Cervical Cancer Patients leukaemia datasets significantly
better, albeit with biologically implausible parameters
(the number of initiated cells at birth is negative), than
a model which assumed just a single pathway [128]. A
number of other such models are described by Tan
[108] and Tan et al. [129], who also discuss at some
length the biological and epidemiological evidence for
such models of carcinogenesis.
We now discuss what may appear to be a special case
of these multiple pathway models, but which are of suf-
ficient flexibility to embrace most categories of multiple
pathway models.
Multiple pathway models incorporating genomic
instability
As discussed in the section “Genomic instability and
somatic cellular Darwinian evolution in cancer” there is
biological data suggesting that the initiating lesion in the
multistage process leading to cancer might be one invol-
ving a destabilization of the genome resulting in eleva-
tion of mutation rates [68,69]. There have been a few
attempts to incorporate GI in mechanistic carcinogen-
esis models [130,131], although in general these models
have not been fitted to data in a statistically rigorous
manner. Little and Wright [5] developed a stochastic
carcinogenesis model which allowed for genome destabi-
lization, very close in spirit to the model of Mao et al.
[130], and generalizing the class of generalized MVK
models developed by Little [4,123,126], which in turn
therefore generalize the two-mutation model of Mool-
g a v k a r ,V e n z o na n dK n u d s o n[ 2 , 3 ] .L i t t l eet al.[ 6 ]
developed a generalization of the model of Little and
Wright [5] that allowed for multiple types of GI, and
have fitted the model to SEER population-based Cauca-
sian colon cancer incidence data.
The more general model of Little et al.[ 6 ]m a k e st h e
following assumptions:
1. Malignancy arises from a series of genetic trans-
formations of a stem cell;
2. Cells can undergo two classes of mutations, can-
cer-stage mutations or destabilizing mutations. Both
are irreversible;
3. Multiple types of GI can occur, which are
mutually exclusive - once cells are committed to a
particular type of GI they and their daughter cells
cannot exhibit any other type of GI;
4. Conditional on their ancestry and model para-
meter history to date, at any stage of the cancer pro-
cess, cells are statistically independent of each other;
5. A tumour cell that has experienced the required
number of cancer mutations will develop into a
clinically detectable tumour.
Cells can acquire up to k successive cancer-stage
mutations, and any of r (mutually exclusive) types of
destabilization mutation(s), e.g., of CIN or MIN type.
Cells become malignant when k cancer-stage mutations
have occurred, no matter how many destabilizing muta-
tions there have been. Once a cell has acquired a desta-
bilizing mutation of type d (1 ≤ d ≤ r), it and its
daughter cells can acquire up to md - 1 further destabi-
lizing mutations of the same type. We define r to be the
multiplicity of destabilization mutation types.I ti st o
be expected that the more destabilizing mutations cells
acquire of each type, the higher the cancer stage muta-
tion rate is, but this is not intrinsic to the model. The
assumption that the r destabilization types are mutually
exclusive is known to be the case for CIN and MIN in
relation to colon and endometrial cancer [27]. The
model is illustrated schematically in Figures 6 and 7.
Cells at different stages of the process are labelled by I
(a, b,d ), where the first subscript, a, represents the num-
ber of cancer stage mutations that the cell has accumu-
lated, the second subscript, b, represents the number of
destabilizing mutations acquired, their type being given
by the third subscript, d. At all stages other than I(0,0,0),
cells are allowed to divide symmetrically or differentiate
(or undergo apoptosis) at rates G(a, b,d )a n dD(a, b,
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daughter cell and another cell with an extra cancer
stage mutation at rate M(a, b,d ). Likewise, cells can
also divide into an equivalent daughter cell and another
cell with an additional destabilizing mutation of type d
at rate A(a, b,d ). The model assumes that there are X(t)
susceptible stem cells at age t. The acquisition of carcino-
genic (cancer-stage) mutations amounts to moving hori-
zontally (left to right) in Figure 6, whereas acquisition of
destabilizing mutations amounts to moving vertically
(top to bottom) in this figure. Further mathematical
details on derivation of the hazard function for this
model are given in Appendix A. The two-mutation MVK
model corresponds to the case k =2 ,r =1 ,m = m1 =0 ,
while the generalized MVK model with K stages devel-
oped by Little [4,123,126] amounts to the case k = K, r =
1, m = m1 = 0. However, in fits to the SEER colon cancer
data, there is little evidencet os u p p o r tt h eh y p o t h e s i s
that the model with more than one type of genomic
instability fits better than models with a single type of
genomic instability [6] (see Figure 8), nor is there evi-
dence that these models fit the data any better than a
model (similar to that used by Luebeck and Moolgavkar
[91]) that did not assume GI [89]. However, Tan and Tan
[132] fitted very similar multiple pathway models to vir-
tually the same SEER data and found stronger evidence
for the involvement of genomic instability. The reasons
for the somewhat different conclusions from our own
probably relate to the incorporation of more biological
data (via highly informative priors) by Tan and Tan
[132], achieved using Bayesian model fitting techniques.
Figure 6 Schematic diagram of generalized cancer model with k cancer-stage mutations and m destabilizing mutations, as in Little
et al. [6]. This corresponds to a single type, d, destabilizing mutation (d Î [1, r]) with m = md destabilizing levels. When there is more than one
type of destabilizing mutation, there are multiple copies of this diagram, glued together along the topmost axis (of cells that have not acquired
a destabilizing mutation), as in Figure 7.
Figure 7 Schematic diagram of the various destabilizing
mutation planes in the model of Little et al. [6], each plane
with the structure of Figure 6. Under the assumption of mutually
exclusive destabilizing mutations, cells that have committed to one
type of GI are not allowed to move between these planes.
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account of problems of parameter identifiability. It has
been known for some time that there is redundancy in
the parameterization of the two-mutation model, so
that only three combinations of the five available com-
binations of model parameters (X, M(0), M(1), G(1), D
(1)) can be estimated from knowledge of the hazard
function [133-135], i.e., two combinations of parameters
cannot be estimated. There is a large literature on this,
the most important parts of which can be found in the
articles of Heidenreich et al. [136] and Hanin [135].
More general material on parameter identifiability and
redundancy can be found in the papers by Rothenberg
[137], Jacquez and Perry [138], Catchpole and Morgan
[139] and Little et al.[ 1 4 0 ] .L i t t l eet al. [141] have
extended the results of Heidenreich [134] and Heiden-
reich et al. [136], showing that for the class of models
considered by Little and Wright [5], that includes the
two-mutation model as a special case, two parameter
combinations cannot be estimated; more generally, for
models of the sort constructed by Little et al. [6] with r
types of destabilization, there are at least r +1p a r a -
meter redundancies, i.e., the number of estimable para-
meters is no more than the number of biological
parameters minus r + 1 [141].
Malignant cell growth and clonal extinction
The models discussed above deal with the generally pro-
longed multistage process whereby a cell and its off-
spring successively accumulate mutations which result
in the production of a cell with a malignant phenotype.
What is usually not modelled is the final (and relatively
short) stage in tumour development, from the appear-
ance of the first malignant cell up to the clinically overt
tumour; this is usually set to some constant (e.g.,
[5,6,114]). However, as noted above, the generalized
multistage models of Little [4], Little and Wright [5]
and Little et al. [6] allow for modelling of a final sto-
chastic-growth or stochastic birth-death process of
tumour growth from the first malignant cell; in particu-
lar this last process could be used to model the “angio-
genic switch”.
There is a large literature on models of tumour
growth and angiogenesis from the appearance of the
first malignant cell, the most recent parts of which we
now briefly review. Basanta et al. [142] use evolutionary
game theory to model glycolysis and its role in tumour
invasion and progression. Komarova et al. [143] utilize a
system of logistic ordinary differential equations (ODE)
to model the total and mutant cell population, in which
mutants are generated by one-stage oncogene activation
Figure 8 Observed colon cancer rate (and 95% CI, adjusted for overdispersion) and model predicted rates for the Caucasian male and
female population, taken from Little et al. [6]. Rates are those predicted by the (single multiplicity) models with two cancer-stage mutations
and one destabilizing mutation and three cancer-stage mutations and one destabilizing mutation. Also shown are the predicted rates for the
models with two cancer-stage mutations with multiplicity two and (1-1) destabilizing mutations (i.e. 2-2-(1-1)), with multiplicity two and (1-2)
destabilizing mutations (i.e. 2-2-(1-2)) and with multiplicity three and (1-1-1) destabilizing mutations (i.e. 2-3-(1-1-1)). The stem cell population is
fixed at 10
8 cells [166].
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Page 11 of 19and two-stage TSG inactivation. D’Onofrio and Gandolfi
[144] model tumour and vascular growth using ODEs,
as also do Ledzewicz and Schättler [145], using also
ideas from optimal control theory. Enderling et al. [146]
employ an agent-based approach to model tumour
growth, migration and cell death; a similar approach is
adopted by Wcisło et al. [147], who also modelled vas-
cular growth. Macklin et al. [148] use solutions of reac-
tion-diffusion partial differential equations (PDE) to
spatially model tumour growth and migration and nutri-
ent supply; a similar approach is adopted by Anderson
[149]. Gatenby et al. [55] present compelling evidence
that, at least for breast cancer, there is late-stage somatic
evolution of epithelial cancer cells entirely within the
space contained by the basement membrane. Gatenby
et al. [55] propose a mathematical model that allows for
somatic evolution in development of breast cancer
resulting in up-regulation of glycolysis to maintain ATP
production despite hypoxia, as well as mutations to
reduce acid-mediated toxicity. Smallbone et al.[ 5 6 ]
develop these ideas and construct a schematic model
that suggests that transient exercise-induced acidosis
may be sufficient to disrupt these critical somatic muta-
tions; this may mediate the observed reduction of cancer
risk with exercise. A problem in all of these papers is
that no attempt has been made to fit the models to bio-
logical or clinical data, and model parameters appear to
have been chosen aribitrarily. Slightly older literature in
this area is reviewed in the text of Adam and Bellomo
[150].
Cell cycle models
The models discussed above inevitably leave out much
biology. One aspect of cancer and normal cell biology
that may be of importance is the cell cycle, because the
cell-cycle checkpoint machinery is critical for DNA
damage and repair, reviewed above, also because of the
known variation of cellular radiosensitivity with cell-
cycle stage [151-153]. Alarcón et al. [154] performed
simulations of the cell cycle in normal and cancer cells
via a system of ODEs. Hazelton [155] outlined simula-
tions using a similar ODE system integrated within a
model of carcinogenesis. A slightly more complex model
is that of Ribba et al. [156], a spatial model of cell-cycle
and cell migration, simulations from which were
employed to assess regulation of tumour growth subject
to radiotherapy. None of these models appear to have
been rigorously fitted to data.
Discussion
All mathematical models make assumptions; these
assumptions simplify the underlying biology, and are
often made for reasons of mathematical or statistical
tractability. We have discussed some of these here, in
particular the critical assumption of somatic cellular
Darwinian evolution, or conditional independence of
transformed cell populations, which we think may be
justified. However, one would be wise to admit that
there is still a lot that is not known about the cancer
process, and to this extent a degree of caution is advised
in using these models.
For example, it is not altogether clear that the
assumption we make that cells can only acquire a single
sort of destabilization is correct. This assumption is
made to simplify the mathematics and is based upon
the inverse relationship observed in colorectal cancer
[27]. Human colorectal cancer cells that exhibit CIN do
not have alterations in the MMR genes whereas cells
with defective MMR mechanism are near diploid and
do not manifest abnormalities associated with CIN [27].
Moreover, the genetic alterations in CIN and MIN cells
are generally distinct. CIN related cell lines have muta-
tions in p53 and APC [157]. In contrast, MIN cells have
frameshift mutations in genes such as b-catenin and
TGF-b RII [158,159], but seldom display p53 and K-ras
mutations [160]. Cell fusion studies also provide insight
into the relationship between CIN and MIN. Lengauer
et al. [75] demonstrated in a cell fusion experiment that
wild-type MMR genes in CIN cells restored MMR func-
tion in MIN cells, resulting in the expression of CIN
but not MIN in a hybrid population of the two cell
types.
As noted in the sub-section “Multiple pathway models
incorporating genomic instability”, there is little evi-
dence to indicate that models with GI, let alone models
that assume multiple types of GI, yield better fit than
models that do not assume GI [6,89] although conclu-
sions at variance with this have been reached by other
modelling groups [132]. One reason could be that data
containing information only on the age distribution of
cancer does not possess the power to discriminate
between models and hence to confirm or to falsify the
hypothesized involvement of GI in colon cancer. Given
how well some of these simpler models fit this data
(e.g., the two cancer-stage one destabilization (2-1)
model), it is perhaps unremarkable that Little et al.[ 6 ]
do not find much improvement in fit offered by the mod-
els that allow for multiple types of GI. It should be noted
that Little et al. [6] are concerned mainly with relative
goodness of fit, as determined, for example, by use of
likelihood ratio tests. Further investigation of minor var-
iant models by Little et al.[ 6 ]d i dn o ts u g g e s tm a r k e d
modifications to these conclusions. These considerations
are also supported by Hornsby et al. [161], who showed
Little Biology Direct 2010, 5:19
http://www.biology-direct.com/content/5/1/19
Page 12 of 19that modest changes in model specification can be diffi-
cult to distinguish in their effect on the cancer incidence
rate. Quantitative information on exposure to various
mutagenic agents (e.g., ionizing radiation) would better
discriminate between models, as would comparison of
the age-specific incidence of inherited and non-inherited
forms of cancer [3,162]. Knudson [3] examined incidence
of inherited and sporadic forms of retinoblastoma and
inferred that two mutations were responsible for indu-
cing this type of tumour. Frank [162] fitted a simple mul-
tistage model, similar to that of Armitage and Doll [1], to
data on retinoblastoma and colorectal cancer. By assum-
ing the inherited form to have one rate-limiting stage less
than its non-inherited counterpart, the ratio of the inci-
dence of non-inherited and inherited forms could be
used to discriminate between models [162]. The colon
cancer data used by Little and Li [89] and Little et al.[ 6 ]
lack information on heritability, but other datasets that
have this information (e.g., [163]) could be used to facili-
tate discrimination between models.
Reviewers’ comments
Comments from Reviewer 1 (RA Gatenby)
A very nice and thorough review. I would like to suggest
that you also consider the role of the unique tumor
environment since Darwinian dynamics consists of both
heritable changes and environmental selection forces
which can be both spatial and temporally heteroge-
neous. Cancers evolve on epithelial surfaces and are
separated from their blood supply by an intact basement
membrane. This creates very specific environmental
selection forces and different stages of premalignant
tumor growth. This allows the specific mutations
observed in cancer to be understood as adaptations to
these microenvironmental factors.
Response to Reviewer 1
Agreed. This is a good point. I have added some extra
sentences in the sub-section “Malignant cell growth and
clonal extinction” making very much these points. I also
refer to these ideas briefly at the start of the section
“Genomic instability and somatic cellular Darwinian
evolution in cancer”.
Comments from Reviewer 2 (M Kimmel)
Recently, there has been a surge in interest in the can-
cerization field theory of carcinogenesis, which states
that as a result of exposure to carcinogens and/or of
inherited genetic variants (mutations), a substantial por-
tion of an organ (called the field) can be enriched in
genetic variants of cells, which then may or may not
acquire further genomic modifications. Cells in the field
may or may not be clonal. The modifications will result
in increased proliferation and invasion of the surround-
ing tissues.
Because of the spatial dimensions of the field, emer-
ging groups of transformed cells (precancerous and
early cancerous tumours) will represent different levels
of transformation, and may exhibit both progression.
They will be frequently multifocal. This viewpoint is in
opposition to the clonal theory of carcinogenesis, which
implies linear irreversible progression and generally uni-
focal lesions. Assuming that the field theory is true, the
models of early cancer growth will have to be revised.
What impact, will this have on models presented in the
current paper?
Response to Reviewer 2
This topic is considered in para. 2 of the section “Geno-
mic instability and somatic cellular Darwinian evolution
in cancer”. I do not judge that the field theory is neces-
sarily in contradiction with the idea of cancer as a fail-
ure of diferentiation. However, I do not think that it can
account for the initiation (rather than progression) of
most tumours, since it demonstrably fails to account for
the clonality that is observed in many cancers, as I point
out in this section.
Appendix A. Details of hazard function derivation
for the model of Little et al. [6]
Let Ya, b,d(t) denote the number of cells with a can-
cer stage mutations, b destabilizing mutations of type
d at time t,a n dYk(t) denote the number of malignant
cells (cells that have acquired k cancer stage muta-
tions). Let us define the full probability generating
function (PGF):
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equations, given by:
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where 0 ≤ a ≤ k -1, 0 ≤ b ≤ md,0≤ d ≤ r,( a, b,d )
≠ (0,0,0), 1d =0is the indicator function defined
by 1
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backward equations for ja, b,d[t, s] are given by
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with the same range for each a, b and d.W ea d o p t
the convention that ,, [,] md d ts   1 0 . The hazard func-
tion, h(t), is the probability that the appearance of the
first tumour cell is at time t, defined by:
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where T is the time that a malignant cell develops for
the first time. As in Little and Wright [5] we can easily
derive:
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In order to calculate the hazard function, we differ-
entiate the backward equations (A2) with respect to t
and obtain the following equations:
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for 0 ≤ a ≤ k-1, 0 ≤ b ≤ md,0≤ d ≤ r and (a, b,d ) ≠
(0,0,0).
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From the forward equations (A1), we can obtain the
boundary conditions for
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By definition, the j’s satisfy the boundary conditions
given by:
  ,,[,, ,, ;,] d tt k 11 10 1 0 1      for  (A6)
Procedures for calculating the hazard function
1. Using the Kolmogorov backward equations
(A2) and their derivatives (A4), regarded, for
fixed t as a set of ordinary differential equations
(with respect to s) in the vector quantity
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together with the boundary conditions (A5) and (A6),
we obtain the solutions for ja, b,d[ 1 ,1 , . . . ,1 ,0 ;t ,s ]
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2. By means of the mathematical trick outlined by Lit-
tle and Wright [5], with little extra work this set of
equations can be augmented to yield the hazard func-
tion and the cumulative hazard function. Let us write:
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Then by (A3) h(t)=g(t, s)|s =0and g(t, s) satisfies:
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3. Now define kts gwsd w
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0   . Then it is readily verified that:
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with the initial condition k(t, t) = 0. Therefore, by aug-
menting the sets of differential equations (A2) and (A4)
with equations (A8) and (A9) we derive the hazard func-
tion and its integral as desired.
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